SARS-CoV-2 is predominantly a respiratory disease that spreads primarily through direct contact (droplets, person to person). However, gastrointestinal (GI) symptoms such as vomiting, nausea, diarrhoea, and abdominal pain are becoming more often recognised as COVID-19 symptoms. Other symptoms of COVID-19, such as dysgeusia and anosmia, have also become more well-known. Studies have also found that these GI symptoms are frequently an early manifestation of Covid-19 and hence a strong predictor of the virus's emergence. There are still many unanswered questions and challenges, such as the relevance of virus detection in asymptomatic subjects' stool/rectal swabs, whether ACE2 is a direct mediator for SARS-CoV-2 entry into the GI tract, and how the virus might survive passage through the digestive system's extreme pH environment. As a result, it's critical to see Covid-19 as more than a respiratory disease and to identify approaches to manage the disease's gastrointestinal component.
Title : Early and late evaluation of esophageal mucosectomy in surgical treatment of advanced esophageal achalasia
Jose Luis Braga De Aquino, Pontifical Catholic University of Campinas, Brazil
Title : How epigastric impedance would radically change gastric medicine
John Andrew Sutton, Invention City, United States
Title : Nanoemulsions as a strategy to enhance gastrointestinal bioavailability and bioactivity of lipid based nutraceuticals
Pubali Dhar, University of Calcutta, India
Title : Professional dining and health
Yaffa Machnes, Bar-Ilan University, Israel
Title : Sickle cell liver disease: A multidisciplinary hemato-hepatology approach
Bandar Aljudaibi, King Faisal Specialists Hospital and Research Centre, Saudi Arabia
Title : From the birth of atoms to life: Iodine and caesium, angels and demons of evolutionary biology, in pancreatic cancer and diabetes
Venturi Sebastiano, Department of Public Health of Romagna, Italy